logo-loader
RNS
AstraZeneca

Total Voting Rights

/**/ em{letter-spacing:.5pt;border:none windowtext 1.0pt;padding:0cm;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .aw{size:21.0cm 842.0pt;margin:3.0cm 72.0pt 0cm 72.0pt;}div.aw{}p.ch{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;line-height:normal}span.cf{font-weight:normal}p.ci{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.cd{font-size:12.0pt;font-family:"Arial","sans-serif"}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";line-height:115%}span.ck{color: black; font-div: italic; line-height: 115%}p.cl{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;text-align:justify;line-height:normal}span.bz{color:windowtext;font-weight:normal} p.cm{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify}p.co{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Arial","sans-serif";color:black;font-weight: bold}span.bv{font-size:10.0pt}span.bt{color:black}span.cp{color:blue;text-decoration:none}span.br{color:blue}span.bq{text-decoration: underline}table.cq{width:446.0pt;margin-left:-5.4pt;border-collapse:collapse}tr.bl{height:21.15pt} td.bo{width:26.68%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}p.cr{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; page-break-after: avoid; text-align: justify; text-indent: -5.5pt}td.bn{width:39.54%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}td.bm{width:33.78%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}tr.bg{height:19.85pt}td.bj{width:26.68%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cs{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt}td.bi{width:39.54%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.bh{width:33.78%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.bf{width:26.68%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt} td.be{width:39.54%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.bd{width:33.78%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}span.bc{font-size:10.0pt; color:black}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt;page-break-after: avoid}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-autospace:none;vertical-align: middle}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}span.ay{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.cw{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";margin-left:3.0pt} /**/
RNS Number : 7771X
AstraZeneca PLC
01 May 2019
 

1 May 2019 15:00 BST

 

 

 

Transparency Directive

Voting Rights and Capital

 

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 April 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,311,759,192 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,311,759,192.

 

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations



Gonzalo Viña

UK/Global

+44 203 749 5916

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Jennifer Hursit

UK/Global

+44 203 749 5762

Christina M Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharma - Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

BioPharma - Respiratory; Renal

+44 203 749 5716

Josie Afolabi

Other

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Jennifer Kretzmann

Retail Investors; Corporate Access

+44 203 749 5824

US toll-free


+1 866 381 72 77




Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRLLFIVEIILIIA

Quick facts: AstraZeneca

Price: £68.48

Market: LSE
Market Cap: £900.61 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE